Antibiotics made to order.
Antibiotics made to order.
复制标题
抗生素按订单生产。
DOI：
10.1126/science.abq3206
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Seipke RF
中科院分区：
文献类型：
--
作者：
Seipke RF
抗菌素耐药性是对人类健康的全球性威胁。迫切需要发现新的抗生素，其作用模式可以绕过普遍存在的临床耐药机制。大多数临床使用的抗生素都是微生物天然产物或其衍生物，其生产是由生物合成基因簇(BGC)编码的。传统的抗生素发现策略包括筛选大型微生物菌株集合以了解抗生素活性，然后对资源密集型的纯材料进行进一步表征。这条管道受到分离未探索的微生物分类群的挑战的阻碍，而且因为大多数BGC在实验室研究期间不表达(，)。在本期的第991页上，Wanget等人使用电子技术发现BGC及其预测产品的化学合成，以确定一种对多药耐药(MDR)临床分离株具有活性的新脂肽。该小组的另一份报告也使用这种方法确定了一种有前途的新抗生素，强调了它的实用性。
Antimicrobial drug resistance is a global threat to human health. There is an urgent need to discover new antibiotics whose modes of action circumvent prevalent clinical resistance mechanisms. Most antibiotics in clinical use are microbial natural products or their derivatives, whose production is encoded by a biosynthetic gene cluster (BGC) . Traditional antibiotic discovery strategies involve screening large microbial strain collections for antibiotic activity, followed by a resource-intensive pursuit of pure material for further characterization. This pipeline is hampered by challenges isolating unexplored microbial taxa and because most BGCs are not expressed during laboratory studies (, ). On page 991 of this issue, Wanget al.use in silico discovery of BGCs and chemical synthesis of their predicted products to identify a new lipopeptide that is active against multidrug-resistant (MDR) clinical isolates. Another report by this group also used this approach to identify a promising new antibiotic , highlighting its utility.